Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Merck’s investigational antiretroviral is a reverse transcriptase¬ translocation inhibitor.
A new survey and educational campaign called “Owning HIV” offer insight.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Merck’s experimental HIV drug proves effective and well tolerated
These three grantees will launch programs thanks to the Merck Foundation’s “HIV Care Connect.”
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.
An OK would add an indication for the use of these HIV medications among those switching from stable regimens.
Here are the HIV treatment news stories with the most views this year.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.
The Impact of Hurricane Maria on HIV
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.